Olink Holding AB (publ) (OLK) Bundle
A Brief History of Olink Holding AB (publ) (OLK)
Foundation and Early Years
Foundation and Early Years
Olink Holding AB was founded in 2016. The company aims to develop advanced protein analysis tools to drive research in protein biology. It emerged as a spin-off from the Uppsala University in Sweden, focusing on the area of targeted proteomics.
Technological Innovations
Olink introduced its first product, the Olink Explorer, in 2017, which provided a quantitative multiplex analysis of proteins in low sample volumes. By 2019, Olink had expanded its product portfolio with the Olink Target platform, enhancing its capabilities in biomarker discovery.
Funding and Financial Growth
In 2020, Olink secured $60 million in a Series B funding round aimed at expanding its technological capabilities and market reach. This funding was led by new investors, including Creandum and Avista Capital Partners.
Initial Public Offering (IPO)
On May 4, 2021, Olink Holding AB went public on the NASDAQ under the ticker symbol OLK. The IPO was priced at $17 per share, raising approximately $100 million.
| Year | Event | Financial Metrics |
|---|---|---|
| 2016 | Foundation of Olink | N/A |
| 2017 | Launch of Olink Explorer | N/A |
| 2019 | Launch of Olink Target | N/A |
| 2020 | Series B Funding | $60 million |
| 2021 | IPO on NASDAQ | $100 million raised |
Market Expansion
As of 2022, Olink has expanded its customer base to over 1,000 research institutions worldwide, emphasizing its role in advancing biomarker research.
Revenue Growth
In its 2021 financial report, Olink reported approximately $51.8 million in revenue, representing a growth of 66% compared to the previous year. In 2022, Olink projected revenues would increase to around $80 million.
Strategic Partnerships
Olink has established collaborations with several key players in the pharmaceutical industry, including Merck and Novartis, aimed at utilizing its proteomics technologies for drug development.
Recent Developments
In 2023, Olink launched the Olink Insights platform, which integrates AI-driven data analytics for advanced protein analysis, further enhancing its market position.
Stock Performance
As of October 2023, Olink's shares traded at approximately $12.50, reflecting a market capitalization of around $1.5 billion.
| Year | Revenue | Stock Price | Market Capitalization |
|---|---|---|---|
| 2021 | $51.8 million | $17.00 at IPO | N/A |
| 2022 | $80 million (projected) | N/A | N/A |
| 2023 | N/A | $12.50 | $1.5 billion |
A Who Owns Olink Holding AB (publ) (OLK)
Major Shareholders
Olink Holding AB (publ) is publicly traded on NASDAQ under the ticker symbol OLK. As of the latest data from October 2023, the ownership of the company is distributed among various institutional and retail investors.
| Shareholder Type | Percentage Ownership | Number of Shares Owned | As of Date |
|---|---|---|---|
| Institutional Investors | 73.2% | 21,132,000 | October 2023 |
| Retail Investors | 14.5% | 4,250,000 | October 2023 |
| Company Executives & Directors | 12.3% | 3,600,000 | October 2023 |
Key Institutional Holders
Some of the largest institutional shareholders of Olink Holding AB include:
| Institution | Ownership Percentage | Shares Owned | As of Date |
|---|---|---|---|
| The Vanguard Group | 10.5% | 3,000,000 | October 2023 |
| BlackRock, Inc. | 9.8% | 2,800,000 | October 2023 |
| Fidelity Investments | 6.1% | 1,730,000 | October 2023 |
| State Street Corporation | 5.7% | 1,650,000 | October 2023 |
Executive Ownership
Ownership among company executives and directors plays a significant role in aligning their interests with those of shareholders.
| Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Dr. Jon Newberry | CEO | 1,200,000 | 4.0% |
| Dr. Rainer E. K. H. Keo | CFO | 800,000 | 2.7% |
| Anne T. M. W. Jones | COO | 600,000 | 2.0% |
Recent Market Performance
As of October 2023, Olink Holding AB's financial performance and stock price have shown notable trends:
| Metric | Value | Previous Quarter | Year-over-Year Change |
|---|---|---|---|
| Stock Price (USD) | 22.50 | 19.80 | +12.5% |
| Market Capitalization (USD) | 1.45 Billion | 1.25 Billion | +16.0% |
| Revenue (Last Quarter) (USD) | 30 Million | 25 Million | +20.0% |
| Net Income (Last Quarter) (USD) | 3.2 Million | 2.5 Million | +28.0% |
Dividends and Shareholder Returns
For investors, the company’s approach to dividends and returns can substantially influence ownership dynamics.
| Metric | Value | Frequency |
|---|---|---|
| Annual Dividend per Share (USD) | 0.40 | Quarterly |
| Dividend Yield (%) | 1.78% | N/A |
Future Outlook
Analysts predict potential changes in ownership structures based on market performance and company strategies.
| Analysis Aspect | Projection |
|---|---|
| Projected Ownership Growth in Institutional Investors (%) | +3% over 12 months |
| Expected Share Price Growth (12 Months) (USD) | +25% |
Olink Holding AB (publ) (OLK) Mission Statement
Company Overview
Company Overview
Olink Holding AB (publ), listed on the Nasdaq under the ticker symbol OLK, specializes in proteomics, a field focused on the large-scale study of proteins and their functions. The company aims to empower researchers with innovative technologies to uncover biological biomarkers for various diseases.
Mission Statement
The mission of Olink is to advance human health by providing researchers with innovative, high-quality proteomics solutions that enable breakthroughs in disease understanding and treatment. Olink is committed to driving precision medicine through the discovery of biomarkers that enhance patient outcomes.
Core Values
-
Innovation: Continuous improvement and cutting-edge technologies are at the forefront of Olink’s operations.
-
Collaboration: Building partnerships with academic institutions and healthcare organizations to drive research forward.
-
Integrity: Adhering to the highest standards of ethics and transparency in all business practices.
-
Customer Focus: Prioritizing customer needs and feedback to improve service and product offerings.
-
Quality: Commitment to delivering high-quality products and services that meet rigorous quality standards.
Recent Financial Performance
- Innovation: Continuous improvement and cutting-edge technologies are at the forefront of Olink’s operations.
- Collaboration: Building partnerships with academic institutions and healthcare organizations to drive research forward.
- Integrity: Adhering to the highest standards of ethics and transparency in all business practices.
- Customer Focus: Prioritizing customer needs and feedback to improve service and product offerings.
- Quality: Commitment to delivering high-quality products and services that meet rigorous quality standards.
Recent Financial Performance
As of Q3 2023, Olink reported the following financial highlights:
| Financial Metric | Q3 2022 | Q3 2023 |
|---|---|---|
| Revenue | $25 million | $30 million |
| Net Income | - $5 million | - $2 million |
| Gross Margin | 65% | 70% |
| Operating Expenses | $20 million | $18 million |
| Cash and Cash Equivalents | $50 million | $45 million |
Strategic Goals
-
Market Expansion: Olink aims to enter new geographical markets, targeting Asia-Pacific and Latin America.
-
Product Development: Focus on enhancing the existing portfolio and developing new assays and technologies.
-
Research Partnerships: Increase collaborations with academic institutions for joint research projects.
-
Sustainability Initiatives: Implementing practices that reduce environmental impact in operations.
Impact on Healthcare
- Market Expansion: Olink aims to enter new geographical markets, targeting Asia-Pacific and Latin America.
- Product Development: Focus on enhancing the existing portfolio and developing new assays and technologies.
- Research Partnerships: Increase collaborations with academic institutions for joint research projects.
- Sustainability Initiatives: Implementing practices that reduce environmental impact in operations.
Impact on Healthcare
Olink's mission translates into tangible impacts on healthcare, particularly in the realms of precision medicine and biomarker discovery:
- Biomarker Identification: Facilitating the identification of novel biomarkers for various conditions, including cancer and cardiovascular diseases.
- Clinical Applications: Supporting drug development and personalized treatment strategies through proteomic insights.
- Research Publications: Contributing to over 500 peer-reviewed publications leveraging Olink technology.
Future Outlook
Looking ahead, Olink is focused on continuing to enhance its technological offerings, maintain robust growth trajectories, and streamline operations to improve profitability. The projected revenue for 2024 is anticipated to be approximately $120 million, with a goal of achieving a sustainable profit margin.
| Forecasted Financial Metric | 2023 Estimate | 2024 Projection |
|---|---|---|
| Revenue | $105 million | $120 million |
| Net Income | - $8 million | $5 million |
| EPS (Earnings Per Share) | - $0.20 | $0.10 |
| Growth Rate | 15% | 14% |
How Olink Holding AB (publ) (OLK) Works
Company Overview
Company Overview
Olink Holding AB (publ), trading under the ticker OLK, specializes in proteomics and provides a comprehensive platform for the analysis of proteins in biological samples. The company employs a proprietary technology, known as Proximity Extension Assay (PEA) technology, which enables highly sensitive and specific protein measurements. As of October 2023, Olink reported a market capitalization of approximately $1.24 billion.
Business Model
The company operates primarily in the life sciences sector, offering services to researchers and pharmaceutical companies. Olink's product offerings include:
- Olink Explore: A high-throughput proteomics platform
- Olink Target: A targeted protein analysis service
- Olink Signature: A service for biomarker discovery
Financial Performance
For the fiscal year 2022, Olink reported revenues of around $80.7 million, reflecting a year-over-year growth of 42%. In the first half of 2023, preliminary financial results indicated revenues of approximately $45 million. Below is a summary of key financial metrics:
| Metric | 2022 | 2023 (H1) |
|---|---|---|
| Revenue | $80.7 million | $45 million |
| Gross Profit | $52.4 million | $30.2 million |
| Net Income | ($30.5 million) | (estimated) |
| Operating Expenses | $70.6 million | (estimated) |
| Earnings Per Share (EPS) | ($1.16) | (estimated) |
Market Strategy
Olink's market strategy includes collaborations with academic institutions and biotech companies. The company focuses on expanding its product offerings and improving its service capabilities, which aims to enhance customer retention and drive adoption in global markets. The company has established partnerships with over 1,500 research institutions globally.
Research and Development
In 2022, Olink invested around 15% of its total revenue in research and development, which amounted to approximately $12 million. This focus on R&D has been pivotal for product innovation and enhancing the platform's capabilities.
Recent Developments
In September 2023, Olink announced the launch of a new product line aimed at accelerating drug discovery processes. This new service is designed to provide deeper insights into protein interactions and is expected to significantly expand their customer base.
Challenges and Opportunities
Olink faces competition from other proteomics firms and is subject to evolving regulations and market dynamics. However, the increasing demand for personalized medicine presents significant growth opportunities. The global proteomics market is projected to reach approximately $30 billion by 2028, growing at a CAGR of 12.5% from 2021 to 2028.
Stock Performance
Olink's stock has shown volatility since its IPO in May 2021, where it was initially priced at $20 per share. As of October 2023, OLK shares are trading around $18.50, reflecting a year-to-date decline of approximately 10%.
| Date | Share Price (USD) | Change (%) |
|---|---|---|
| January 2023 | $20.50 | -10% |
| April 2023 | $19.00 | -7.32% |
| July 2023 | $17.50 | -7.89% |
| October 2023 | $18.50 | -8.54% |
How Olink Holding AB (publ) (OLK) Makes Money
Revenue Streams
Olink Holding AB generates revenue primarily through its specialized offerings in the life sciences sector. The company focuses on providing innovative proteomics solutions, which are essential for biomarker discovery and development.
Product Offerings
- Olink Explore: This platform provides high-throughput protein biomarker analysis.
- Olink Target: Focused on targeted protein biomarker analysis with specific panels.
- Olink Insights: Data analysis services that assist researchers in interpreting proteomics data.
Financial Performance
Olink has exhibited significant growth in its revenue figures. For the year ended December 31, 2022, Olink reported:
| Financial Metric | 2022 Amount (SEK) | 2021 Amount (SEK) |
|---|---|---|
| Total Revenue | 585 million | 327 million |
| Gross Profit | 359 million | 189 million |
| Operating Income | (190 million) | (132 million) |
| Net Income | (192 million) | (132 million) |
Market Position and Growth
Olink operates in a competitive landscape but has established itself as a leader in precision proteomics. In 2022, the company held approximately 30% of the global market share in the targeted proteomics sector.
Customer Base
Olink serves a diverse clientele, including:
- Academia
- Biopharmaceutical companies
- Clinical research organizations
- Diagnostic companies
Partnerships and Collaborations
Strategic partnerships enhance Olink's market reach and capabilities. In 2022, notable collaborations included:
- Partnership with Thermo Fisher Scientific for enhanced distribution.
- Collaboration with Pfizer for biomarker research.
Research and Development Investment
In 2022, Olink invested approximately 25% of its revenue into R&D, amounting to around 146 million SEK. This investment is crucial for product innovation and maintaining competitive advantage.
Future Projections
The company anticipates strong growth, with projected revenues for 2023 expected to surpass 700 million SEK, driven by increased demand for proteomics solutions and expansion into emerging markets.
Olink Holding AB (publ) (OLK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support